Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.33 |
| ▸ | LOX | P28300 | 2/20 | 0.33 |
| ▸ | AR | P10275 | 3/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30527951 | 1.00 | TDP1 (0.39) | TDP1PARP1IDO1LOXL2LOX | |
| SCHEMBL17242089 | 0.88 | PARP1 (0.36) | PARP1IDO1LOXL2LOXAR | |
| SCHEMBL1639940 | 0.82 | — | — | |
| SCHEMBL30514178 | 0.82 | — | — | |
| SCHEMBL17241807 | 0.81 | ALDH1A1 (0.39) | PARP1IDO1LOXL2LOXAR | |
| SCHEMBL16635231 | 0.81 | LOXL2 (0.50) | TDP1PARP1LOXL2LOXRECQL | |
| SCHEMBL1870454 | 0.81 | KDM4E (0.42) | TDP1PARP1IDO1LOXL2LOX | |
| SCHEMBL1874470 | 0.81 | NOS2 (0.39) | PARP1IDO1LOXL2LOXAR | |
| Bromide SCHEMBL3197680 | 0.80 | PARP1 (0.39) | PARP1IDO1LOXL2LOXAR | |
| Hydrochloric Acid SCHEMBL14157208 | 0.79 | LOXL2 (0.48) | TDP1LOXL2LOXRECQLLOXL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023131951-A1 | NOVEL DERIVATIVES OF NON-CODED AMINO ACIDS AND THEIR USE AS HERBICIDES | FORTEPHEST LTD. (IL) | 2023-07-13 | — | — | WO | claimed |
| US-20240284907-A1 | NOVEL DERIVATIVES OF NON-CODED AMINO ACIDS AND THEIR USE AS HERBICIDES | FORTEPHEST LTD. (IL) | 2024-08-29 | — | — | US | disclosed |
| WO-2023131951-A1 | NOVEL DERIVATIVES OF NON-CODED AMINO ACIDS AND THEIR USE AS HERBICIDES | FORTEPHEST LTD. (IL) | 2023-07-13 | — | — | WO | disclosed |
| US-9839642-B2 | Beta-tetrazolyl-propionic acids as metallo-beta-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170173035-A1 | BETA-TETRAZOLYL-PROPIONIC ACIDS AS METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-06-22 | — | — | US | disclosed |
| EP-3139918-A1 | BETA-TETRAZOLYL-PROPIONIC ACIDS AS METALLO-BETA-LACTAMASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-03-15 | — | — | EP | disclosed |
| CN-105377857-A | Novel azabenzimidazole derivatives | BOEHRINGER INGELHEIM INT | 2016-03-02 | — | — | CN | disclosed |
| CN-102666541-B | Purine or deazapurine derivatives for the treatment of, in particular, viral infections | GILEAD SCIENCES, INC. (US) | 2015-11-25 | — | — | CN | disclosed |
| WO-2015171474-A1 | BETA-TETRAZOLYL-PROPIONIC ACIDS AS METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-11-12 | — | — | WO | disclosed |
| CN-102666541-A | Purine or deazapurine derivatives for the treatment of, in particular, viral infections | GILEAD SCIENCES INC | 2012-09-12 | — | — | CN | disclosed |
| CN-102282142-A | Substituted aryl compounds and their use | — | 2011-12-14 | — | — | CN | disclosed |
| CN-102282143-A | Heterocyclically substituted aryl compounds and application thereof | — | 2011-12-14 | — | — | CN | disclosed |
| CN-1768054-A | Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | AVENTIS PHARMA SA (FR) | 2006-05-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170173035-A1 | BETA-TETRAZOLYL-PROPIONIC ACIDS AS METALLO-BETA-LACTAMASE INHIBITORS | MGAM, CMBL, PEPD | TDP1 4057/4885PARP1 2625/4885IDO1 1974/4885 |
| US-20240284907-A1 | NOVEL DERIVATIVES OF NON-CODED AMINO ACIDS AND THEIR USE AS HERBICIDES | DDT, DDC, GLUL | TDP1 2949/4885PARP1 4775/4885IDO1 886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.